Utah Medical Products, Inc.
Utah Medical Products, Inc. (UTMD) Stock Competitors & Peer Comparison
See (UTMD) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| UTMD | $66.94 | -1.30% | 214.5M | 19.24 | $3.48 | +1.80% |
| ISRG | $492.10 | -2.37% | 174.8B | 62.37 | $7.89 | N/A |
| BDX | $184.34 | -0.57% | 66.7B | 30.15 | $6.11 | +1.78% |
| BDXA | $59.24 | -2.24% | 55.9B | 21.44 | $2.76 | +1.78% |
| ALC | $82.85 | +0.27% | 41B | 39.46 | $2.10 | +0.41% |
| MDLN | $49.64 | -0.32% | 40.3B | 71.94 | $0.69 | N/A |
| RMD | $260.79 | +0.64% | 38.1B | 25.83 | $10.10 | +0.90% |
| WST | $244.22 | +1.29% | 17.6B | 35.91 | $6.80 | +0.36% |
| HOLX | $75.44 | +0.01% | 16.8B | 31.30 | $2.41 | N/A |
| COO | $82.94 | -1.34% | 16.5B | 44.35 | $1.87 | N/A |
Stock Comparison
UTMD vs ISRG Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, ISRG has a market cap of 174.8B. Regarding current trading prices, UTMD is priced at $66.94, while ISRG trades at $492.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas ISRG's P/E ratio is 62.37. In terms of profitability, UTMD's ROE is +0.10%, compared to ISRG's ROE of +0.16%. Regarding short-term risk, UTMD is less volatile compared to ISRG. This indicates potentially lower risk in terms of short-term price fluctuations for UTMD.Check ISRG's competition here
UTMD vs BDX Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, BDX has a market cap of 66.7B. Regarding current trading prices, UTMD is priced at $66.94, while BDX trades at $184.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas BDX's P/E ratio is 30.15. In terms of profitability, UTMD's ROE is +0.10%, compared to BDX's ROE of +0.07%. Regarding short-term risk, UTMD is less volatile compared to BDX. This indicates potentially lower risk in terms of short-term price fluctuations for UTMD.Check BDX's competition here
UTMD vs BDXA Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, UTMD is priced at $66.94, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas BDXA's P/E ratio is 21.44. In terms of profitability, UTMD's ROE is +0.10%, compared to BDXA's ROE of +0.07%. Regarding short-term risk, UTMD is less volatile compared to BDXA. This indicates potentially lower risk in terms of short-term price fluctuations for UTMD.Check BDXA's competition here
UTMD vs ALC Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, ALC has a market cap of 41B. Regarding current trading prices, UTMD is priced at $66.94, while ALC trades at $82.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas ALC's P/E ratio is 39.46. In terms of profitability, UTMD's ROE is +0.10%, compared to ALC's ROE of +0.05%. Regarding short-term risk, UTMD is more volatile compared to ALC. This indicates potentially higher risk in terms of short-term price fluctuations for UTMD.Check ALC's competition here
UTMD vs MDLN Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, MDLN has a market cap of 40.3B. Regarding current trading prices, UTMD is priced at $66.94, while MDLN trades at $49.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas MDLN's P/E ratio is 71.94. In terms of profitability, UTMD's ROE is +0.10%, compared to MDLN's ROE of +0.08%. Regarding short-term risk, UTMD is more volatile compared to MDLN. This indicates potentially higher risk in terms of short-term price fluctuations for UTMD.Check MDLN's competition here
UTMD vs RMD Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, RMD has a market cap of 38.1B. Regarding current trading prices, UTMD is priced at $66.94, while RMD trades at $260.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas RMD's P/E ratio is 25.83. In terms of profitability, UTMD's ROE is +0.10%, compared to RMD's ROE of +0.25%. Regarding short-term risk, UTMD is less volatile compared to RMD. This indicates potentially lower risk in terms of short-term price fluctuations for UTMD.Check RMD's competition here
UTMD vs WST Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, WST has a market cap of 17.6B. Regarding current trading prices, UTMD is priced at $66.94, while WST trades at $244.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas WST's P/E ratio is 35.91. In terms of profitability, UTMD's ROE is +0.10%, compared to WST's ROE of +0.17%. Regarding short-term risk, UTMD is less volatile compared to WST. This indicates potentially lower risk in terms of short-term price fluctuations for UTMD.Check WST's competition here
UTMD vs HOLX Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, HOLX has a market cap of 16.8B. Regarding current trading prices, UTMD is priced at $66.94, while HOLX trades at $75.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas HOLX's P/E ratio is 31.30. In terms of profitability, UTMD's ROE is +0.10%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, UTMD is more volatile compared to HOLX. This indicates potentially higher risk in terms of short-term price fluctuations for UTMD.Check HOLX's competition here
UTMD vs COO Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, COO has a market cap of 16.5B. Regarding current trading prices, UTMD is priced at $66.94, while COO trades at $82.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas COO's P/E ratio is 44.35. In terms of profitability, UTMD's ROE is +0.10%, compared to COO's ROE of +0.05%. Regarding short-term risk, UTMD is less volatile compared to COO. This indicates potentially lower risk in terms of short-term price fluctuations for UTMD.Check COO's competition here
UTMD vs BDXB Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, UTMD is priced at $66.94, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas BDXB's P/E ratio is 7.60. In terms of profitability, UTMD's ROE is +0.10%, compared to BDXB's ROE of +0.07%. Regarding short-term risk, UTMD is less volatile compared to BDXB. This indicates potentially lower risk in terms of short-term price fluctuations for UTMD.Check BDXB's competition here
UTMD vs BAX Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, BAX has a market cap of 10.9B. Regarding current trading prices, UTMD is priced at $66.94, while BAX trades at $21.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas BAX's P/E ratio is -12.16. In terms of profitability, UTMD's ROE is +0.10%, compared to BAX's ROE of -0.12%. Regarding short-term risk, UTMD is less volatile compared to BAX. This indicates potentially lower risk in terms of short-term price fluctuations for UTMD.Check BAX's competition here
UTMD vs ATR Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, ATR has a market cap of 9.6B. Regarding current trading prices, UTMD is priced at $66.94, while ATR trades at $145.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas ATR's P/E ratio is 24.74. In terms of profitability, UTMD's ROE is +0.10%, compared to ATR's ROE of +0.15%. Regarding short-term risk, UTMD is less volatile compared to ATR. This indicates potentially lower risk in terms of short-term price fluctuations for UTMD.Check ATR's competition here
UTMD vs MASI Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, UTMD is priced at $66.94, while MASI trades at $175.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas MASI's P/E ratio is -38.52. In terms of profitability, UTMD's ROE is +0.10%, compared to MASI's ROE of -0.59%. Regarding short-term risk, UTMD is more volatile compared to MASI. This indicates potentially higher risk in terms of short-term price fluctuations for UTMD.Check MASI's competition here
UTMD vs RGEN Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, RGEN has a market cap of 7.6B. Regarding current trading prices, UTMD is priced at $66.94, while RGEN trades at $135.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas RGEN's P/E ratio is 13540.00. In terms of profitability, UTMD's ROE is +0.10%, compared to RGEN's ROE of +0.00%. Regarding short-term risk, UTMD is less volatile compared to RGEN. This indicates potentially lower risk in terms of short-term price fluctuations for UTMD.Check RGEN's competition here
UTMD vs BLCO Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, BLCO has a market cap of 6.4B. Regarding current trading prices, UTMD is priced at $66.94, while BLCO trades at $17.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas BLCO's P/E ratio is -20.90. In terms of profitability, UTMD's ROE is +0.10%, compared to BLCO's ROE of -0.06%. Regarding short-term risk, UTMD is less volatile compared to BLCO. This indicates potentially lower risk in terms of short-term price fluctuations for UTMD.Check BLCO's competition here
UTMD vs AVTR Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, AVTR has a market cap of 6.1B. Regarding current trading prices, UTMD is priced at $66.94, while AVTR trades at $8.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas AVTR's P/E ratio is -11.38. In terms of profitability, UTMD's ROE is +0.10%, compared to AVTR's ROE of -0.09%. Regarding short-term risk, UTMD is less volatile compared to AVTR. This indicates potentially lower risk in terms of short-term price fluctuations for UTMD.Check AVTR's competition here
UTMD vs TFX Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, TFX has a market cap of 5B. Regarding current trading prices, UTMD is priced at $66.94, while TFX trades at $113.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas TFX's P/E ratio is -15.77. In terms of profitability, UTMD's ROE is +0.10%, compared to TFX's ROE of -0.08%. Regarding short-term risk, UTMD is less volatile compared to TFX. This indicates potentially lower risk in terms of short-term price fluctuations for UTMD.Check TFX's competition here
UTMD vs MMSI Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, MMSI has a market cap of 4.8B. Regarding current trading prices, UTMD is priced at $66.94, while MMSI trades at $81.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas MMSI's P/E ratio is 41.85. In terms of profitability, UTMD's ROE is +0.10%, compared to MMSI's ROE of +0.08%. Regarding short-term risk, UTMD is less volatile compared to MMSI. This indicates potentially lower risk in terms of short-term price fluctuations for UTMD.Check MMSI's competition here
UTMD vs STVN Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, STVN has a market cap of 4.4B. Regarding current trading prices, UTMD is priced at $66.94, while STVN trades at $16.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas STVN's P/E ratio is 26.30. In terms of profitability, UTMD's ROE is +0.10%, compared to STVN's ROE of +0.10%. Regarding short-term risk, UTMD is less volatile compared to STVN. This indicates potentially lower risk in terms of short-term price fluctuations for UTMD.Check STVN's competition here
UTMD vs ICUI Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, ICUI has a market cap of 3.7B. Regarding current trading prices, UTMD is priced at $66.94, while ICUI trades at $151.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas ICUI's P/E ratio is -488.94. In terms of profitability, UTMD's ROE is +0.10%, compared to ICUI's ROE of +0.00%. Regarding short-term risk, UTMD is less volatile compared to ICUI. This indicates potentially lower risk in terms of short-term price fluctuations for UTMD.Check ICUI's competition here
UTMD vs HAE Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, HAE has a market cap of 2.9B. Regarding current trading prices, UTMD is priced at $66.94, while HAE trades at $61.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas HAE's P/E ratio is 16.88. In terms of profitability, UTMD's ROE is +0.10%, compared to HAE's ROE of +0.20%. Regarding short-term risk, UTMD is less volatile compared to HAE. This indicates potentially lower risk in terms of short-term price fluctuations for UTMD.Check HAE's competition here
UTMD vs WRBY Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, WRBY has a market cap of 2.7B. Regarding current trading prices, UTMD is priced at $66.94, while WRBY trades at $22.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas WRBY's P/E ratio is -277.50. In terms of profitability, UTMD's ROE is +0.10%, compared to WRBY's ROE of +0.00%. Regarding short-term risk, UTMD is less volatile compared to WRBY. This indicates potentially lower risk in terms of short-term price fluctuations for UTMD.Check WRBY's competition here
UTMD vs XRAY Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, XRAY has a market cap of 2.5B. Regarding current trading prices, UTMD is priced at $66.94, while XRAY trades at $12.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas XRAY's P/E ratio is -2.85. In terms of profitability, UTMD's ROE is +0.10%, compared to XRAY's ROE of -0.48%. Regarding short-term risk, UTMD is less volatile compared to XRAY. This indicates potentially lower risk in terms of short-term price fluctuations for UTMD.Check XRAY's competition here
UTMD vs LMAT Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, LMAT has a market cap of 2.1B. Regarding current trading prices, UTMD is priced at $66.94, while LMAT trades at $91.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas LMAT's P/E ratio is 39.39. In terms of profitability, UTMD's ROE is +0.10%, compared to LMAT's ROE of +0.15%. Regarding short-term risk, UTMD is less volatile compared to LMAT. This indicates potentially lower risk in terms of short-term price fluctuations for UTMD.Check LMAT's competition here
UTMD vs ATRC Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, ATRC has a market cap of 1.6B. Regarding current trading prices, UTMD is priced at $66.94, while ATRC trades at $31.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas ATRC's P/E ratio is -52.11. In terms of profitability, UTMD's ROE is +0.10%, compared to ATRC's ROE of -0.02%. Regarding short-term risk, UTMD is less volatile compared to ATRC. This indicates potentially lower risk in terms of short-term price fluctuations for UTMD.Check ATRC's competition here
UTMD vs KMTS Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, KMTS has a market cap of 1.6B. Regarding current trading prices, UTMD is priced at $66.94, while KMTS trades at $26.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas KMTS's P/E ratio is -6.54. In terms of profitability, UTMD's ROE is +0.10%, compared to KMTS's ROE of -1.89%. Regarding short-term risk, UTMD is less volatile compared to KMTS. This indicates potentially lower risk in terms of short-term price fluctuations for UTMD.Check KMTS's competition here
UTMD vs QDEL Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, QDEL has a market cap of 1.4B. Regarding current trading prices, UTMD is priced at $66.94, while QDEL trades at $21.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas QDEL's P/E ratio is -1.27. In terms of profitability, UTMD's ROE is +0.10%, compared to QDEL's ROE of -0.46%. Regarding short-term risk, UTMD is less volatile compared to QDEL. This indicates potentially lower risk in terms of short-term price fluctuations for UTMD.Check QDEL's competition here
UTMD vs PLSE Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, PLSE has a market cap of 1.4B. Regarding current trading prices, UTMD is priced at $66.94, while PLSE trades at $20.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas PLSE's P/E ratio is -17.71. In terms of profitability, UTMD's ROE is +0.10%, compared to PLSE's ROE of -0.73%. Regarding short-term risk, UTMD is less volatile compared to PLSE. This indicates potentially lower risk in terms of short-term price fluctuations for UTMD.Check PLSE's competition here
UTMD vs AZTA Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, AZTA has a market cap of 1.3B. Regarding current trading prices, UTMD is priced at $66.94, while AZTA trades at $28.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas AZTA's P/E ratio is 48.33. In terms of profitability, UTMD's ROE is +0.10%, compared to AZTA's ROE of -0.03%. Regarding short-term risk, UTMD is less volatile compared to AZTA. This indicates potentially lower risk in terms of short-term price fluctuations for UTMD.Check AZTA's competition here
UTMD vs NVCR Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, NVCR has a market cap of 1.2B. Regarding current trading prices, UTMD is priced at $66.94, while NVCR trades at $10.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas NVCR's P/E ratio is -6.82. In terms of profitability, UTMD's ROE is +0.10%, compared to NVCR's ROE of -0.50%. Regarding short-term risk, UTMD is less volatile compared to NVCR. This indicates potentially lower risk in terms of short-term price fluctuations for UTMD.Check NVCR's competition here
UTMD vs BLFS Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, BLFS has a market cap of 1.1B. Regarding current trading prices, UTMD is priced at $66.94, while BLFS trades at $22.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas BLFS's P/E ratio is -60.21. In terms of profitability, UTMD's ROE is +0.10%, compared to BLFS's ROE of -0.01%. Regarding short-term risk, UTMD is less volatile compared to BLFS. This indicates potentially lower risk in terms of short-term price fluctuations for UTMD.Check BLFS's competition here
UTMD vs NNNN Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, NNNN has a market cap of 1.1B. Regarding current trading prices, UTMD is priced at $66.94, while NNNN trades at $24.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas NNNN's P/E ratio is 410.33. In terms of profitability, UTMD's ROE is +0.10%, compared to NNNN's ROE of +0.11%. Regarding short-term risk, UTMD is less volatile compared to NNNN. This indicates potentially lower risk in terms of short-term price fluctuations for UTMD.Check NNNN's competition here
UTMD vs STAA Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, STAA has a market cap of 898.5M. Regarding current trading prices, UTMD is priced at $66.94, while STAA trades at $18.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas STAA's P/E ratio is -9.29. In terms of profitability, UTMD's ROE is +0.10%, compared to STAA's ROE of -0.27%. Regarding short-term risk, UTMD is less volatile compared to STAA. This indicates potentially lower risk in terms of short-term price fluctuations for UTMD.Check STAA's competition here
UTMD vs ATRI Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, UTMD is priced at $66.94, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas ATRI's P/E ratio is 64.50. In terms of profitability, UTMD's ROE is +0.10%, compared to ATRI's ROE of +0.08%. Regarding short-term risk, UTMD is more volatile compared to ATRI. This indicates potentially higher risk in terms of short-term price fluctuations for UTMD.Check ATRI's competition here
UTMD vs ANGO Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, ANGO has a market cap of 462M. Regarding current trading prices, UTMD is priced at $66.94, while ANGO trades at $11.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas ANGO's P/E ratio is -16.73. In terms of profitability, UTMD's ROE is +0.10%, compared to ANGO's ROE of -0.15%. Regarding short-term risk, UTMD is less volatile compared to ANGO. This indicates potentially lower risk in terms of short-term price fluctuations for UTMD.Check ANGO's competition here
UTMD vs KRMD Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, KRMD has a market cap of 221.9M. Regarding current trading prices, UTMD is priced at $66.94, while KRMD trades at $4.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas KRMD's P/E ratio is -59.87. In terms of profitability, UTMD's ROE is +0.10%, compared to KRMD's ROE of -0.22%. Regarding short-term risk, UTMD is less volatile compared to KRMD. This indicates potentially lower risk in terms of short-term price fluctuations for UTMD.Check KRMD's competition here
UTMD vs OSUR Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, OSUR has a market cap of 201.1M. Regarding current trading prices, UTMD is priced at $66.94, while OSUR trades at $2.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas OSUR's P/E ratio is -3.40. In terms of profitability, UTMD's ROE is +0.10%, compared to OSUR's ROE of -0.16%. Regarding short-term risk, UTMD is less volatile compared to OSUR. This indicates potentially lower risk in terms of short-term price fluctuations for UTMD.Check OSUR's competition here
UTMD vs STXS Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, STXS has a market cap of 199.2M. Regarding current trading prices, UTMD is priced at $66.94, while STXS trades at $2.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas STXS's P/E ratio is -7.36. In terms of profitability, UTMD's ROE is +0.10%, compared to STXS's ROE of -2.49%. Regarding short-term risk, UTMD is less volatile compared to STXS. This indicates potentially lower risk in terms of short-term price fluctuations for UTMD.Check STXS's competition here
UTMD vs SMTI Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, SMTI has a market cap of 185.1M. Regarding current trading prices, UTMD is priced at $66.94, while SMTI trades at $20.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas SMTI's P/E ratio is -28.78. In terms of profitability, UTMD's ROE is +0.10%, compared to SMTI's ROE of -1.28%. Regarding short-term risk, UTMD is less volatile compared to SMTI. This indicates potentially lower risk in terms of short-term price fluctuations for UTMD.Check SMTI's competition here
UTMD vs NYXH Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, NYXH has a market cap of 165.4M. Regarding current trading prices, UTMD is priced at $66.94, while NYXH trades at $4.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas NYXH's P/E ratio is -1.67. In terms of profitability, UTMD's ROE is +0.10%, compared to NYXH's ROE of -1.01%. Regarding short-term risk, UTMD is less volatile compared to NYXH. This indicates potentially lower risk in terms of short-term price fluctuations for UTMD.Check NYXH's competition here
UTMD vs INFU Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, INFU has a market cap of 154.8M. Regarding current trading prices, UTMD is priced at $66.94, while INFU trades at $7.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas INFU's P/E ratio is 29.27. In terms of profitability, UTMD's ROE is +0.10%, compared to INFU's ROE of +0.10%. Regarding short-term risk, UTMD is less volatile compared to INFU. This indicates potentially lower risk in terms of short-term price fluctuations for UTMD.Check INFU's competition here
UTMD vs PDEX Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, PDEX has a market cap of 131.7M. Regarding current trading prices, UTMD is priced at $66.94, while PDEX trades at $40.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas PDEX's P/E ratio is 11.84. In terms of profitability, UTMD's ROE is +0.10%, compared to PDEX's ROE of +0.29%. Regarding short-term risk, UTMD is less volatile compared to PDEX. This indicates potentially lower risk in terms of short-term price fluctuations for UTMD.Check PDEX's competition here
UTMD vs MBOT Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, MBOT has a market cap of 93.4M. Regarding current trading prices, UTMD is priced at $66.94, while MBOT trades at $2.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas MBOT's P/E ratio is -4.56. In terms of profitability, UTMD's ROE is +0.10%, compared to MBOT's ROE of -0.37%. Regarding short-term risk, UTMD is less volatile compared to MBOT. This indicates potentially lower risk in terms of short-term price fluctuations for UTMD.Check MBOT's competition here
UTMD vs AKYA Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, UTMD is priced at $66.94, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas AKYA's P/E ratio is -1.34. In terms of profitability, UTMD's ROE is +0.10%, compared to AKYA's ROE of -6.72%. Regarding short-term risk, UTMD is more volatile compared to AKYA. This indicates potentially higher risk in terms of short-term price fluctuations for UTMD.Check AKYA's competition here
UTMD vs DXR Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, DXR has a market cap of 62.9M. Regarding current trading prices, UTMD is priced at $66.94, while DXR trades at $12.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas DXR's P/E ratio is 77.97. In terms of profitability, UTMD's ROE is +0.10%, compared to DXR's ROE of +0.05%. Regarding short-term risk, UTMD is more volatile compared to DXR. This indicates potentially higher risk in terms of short-term price fluctuations for UTMD.Check DXR's competition here
UTMD vs ZTEK Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, ZTEK has a market cap of 61.8M. Regarding current trading prices, UTMD is priced at $66.94, while ZTEK trades at $0.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas ZTEK's P/E ratio is -8.23. In terms of profitability, UTMD's ROE is +0.10%, compared to ZTEK's ROE of -0.61%. Regarding short-term risk, UTMD is less volatile compared to ZTEK. This indicates potentially lower risk in terms of short-term price fluctuations for UTMD.Check ZTEK's competition here
UTMD vs STSS Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, STSS has a market cap of 52.9M. Regarding current trading prices, UTMD is priced at $66.94, while STSS trades at $1.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas STSS's P/E ratio is N/A. In terms of profitability, UTMD's ROE is +0.10%, compared to STSS's ROE of -0.91%. Regarding short-term risk, UTMD is less volatile compared to STSS. This indicates potentially lower risk in terms of short-term price fluctuations for UTMD.Check STSS's competition here
UTMD vs OMIC Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, UTMD is priced at $66.94, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas OMIC's P/E ratio is -0.58. In terms of profitability, UTMD's ROE is +0.10%, compared to OMIC's ROE of -0.43%. Regarding short-term risk, UTMD is more volatile compared to OMIC. This indicates potentially higher risk in terms of short-term price fluctuations for UTMD.Check OMIC's competition here
UTMD vs IGAP Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, UTMD is priced at $66.94, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas IGAP's P/E ratio is -10.52. In terms of profitability, UTMD's ROE is +0.10%, compared to IGAP's ROE of +1.21%. Regarding short-term risk, UTMD is less volatile compared to IGAP. This indicates potentially lower risk in terms of short-term price fluctuations for UTMD.Check IGAP's competition here
UTMD vs NEPH Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, NEPH has a market cap of 40.1M. Regarding current trading prices, UTMD is priced at $66.94, while NEPH trades at $3.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas NEPH's P/E ratio is 26.93. In terms of profitability, UTMD's ROE is +0.10%, compared to NEPH's ROE of +0.16%. Regarding short-term risk, UTMD is less volatile compared to NEPH. This indicates potentially lower risk in terms of short-term price fluctuations for UTMD.Check NEPH's competition here
UTMD vs POCI Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, POCI has a market cap of 33.5M. Regarding current trading prices, UTMD is priced at $66.94, while POCI trades at $4.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas POCI's P/E ratio is -5.11. In terms of profitability, UTMD's ROE is +0.10%, compared to POCI's ROE of -0.61%. Regarding short-term risk, UTMD is less volatile compared to POCI. This indicates potentially lower risk in terms of short-term price fluctuations for UTMD.Check POCI's competition here
UTMD vs SDC Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, UTMD is priced at $66.94, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas SDC's P/E ratio is -0.03. In terms of profitability, UTMD's ROE is +0.10%, compared to SDC's ROE of -1.96%. Regarding short-term risk, UTMD is less volatile compared to SDC. This indicates potentially lower risk in terms of short-term price fluctuations for UTMD.Check SDC's competition here
UTMD vs EKSO Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, EKSO has a market cap of 27.9M. Regarding current trading prices, UTMD is priced at $66.94, while EKSO trades at $10.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas EKSO's P/E ratio is -1.98. In terms of profitability, UTMD's ROE is +0.10%, compared to EKSO's ROE of -0.91%. Regarding short-term risk, UTMD is less volatile compared to EKSO. This indicates potentially lower risk in terms of short-term price fluctuations for UTMD.Check EKSO's competition here
UTMD vs HBIO Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, HBIO has a market cap of 25.4M. Regarding current trading prices, UTMD is priced at $66.94, while HBIO trades at $0.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas HBIO's P/E ratio is -0.47. In terms of profitability, UTMD's ROE is +0.10%, compared to HBIO's ROE of -1.99%. Regarding short-term risk, UTMD is less volatile compared to HBIO. This indicates potentially lower risk in terms of short-term price fluctuations for UTMD.Check HBIO's competition here
UTMD vs IVC Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, UTMD is priced at $66.94, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas IVC's P/E ratio is -0.79. In terms of profitability, UTMD's ROE is +0.10%, compared to IVC's ROE of -0.46%. Regarding short-term risk, UTMD is less volatile compared to IVC. This indicates potentially lower risk in terms of short-term price fluctuations for UTMD.Check IVC's competition here
UTMD vs ZJYL Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, ZJYL has a market cap of 22.4M. Regarding current trading prices, UTMD is priced at $66.94, while ZJYL trades at $0.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas ZJYL's P/E ratio is 14.33. In terms of profitability, UTMD's ROE is +0.10%, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, UTMD is less volatile compared to ZJYL. This indicates potentially lower risk in terms of short-term price fluctuations for UTMD.Check ZJYL's competition here
UTMD vs MLSS Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, MLSS has a market cap of 20M. Regarding current trading prices, UTMD is priced at $66.94, while MLSS trades at $0.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas MLSS's P/E ratio is -2.83. In terms of profitability, UTMD's ROE is +0.10%, compared to MLSS's ROE of -1.65%. Regarding short-term risk, UTMD is less volatile compared to MLSS. This indicates potentially lower risk in terms of short-term price fluctuations for UTMD.Check MLSS's competition here
UTMD vs RVP Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, RVP has a market cap of 19.8M. Regarding current trading prices, UTMD is priced at $66.94, while RVP trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas RVP's P/E ratio is -3.00. In terms of profitability, UTMD's ROE is +0.10%, compared to RVP's ROE of -0.08%. Regarding short-term risk, UTMD is more volatile compared to RVP. This indicates potentially higher risk in terms of short-term price fluctuations for UTMD.Check RVP's competition here
UTMD vs FEMY Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, FEMY has a market cap of 16.2M. Regarding current trading prices, UTMD is priced at $66.94, while FEMY trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas FEMY's P/E ratio is -0.80. In terms of profitability, UTMD's ROE is +0.10%, compared to FEMY's ROE of -7.64%. Regarding short-term risk, UTMD is less volatile compared to FEMY. This indicates potentially lower risk in terms of short-term price fluctuations for UTMD.Check FEMY's competition here
UTMD vs RGNT Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, RGNT has a market cap of 14.5M. Regarding current trading prices, UTMD is priced at $66.94, while RGNT trades at $3.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas RGNT's P/E ratio is -3.35. In terms of profitability, UTMD's ROE is +0.10%, compared to RGNT's ROE of N/A. Regarding short-term risk, UTMD is less volatile compared to RGNT. This indicates potentially lower risk in terms of short-term price fluctuations for UTMD.Check RGNT's competition here
UTMD vs NXGL Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, NXGL has a market cap of 12.7M. Regarding current trading prices, UTMD is priced at $66.94, while NXGL trades at $1.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas NXGL's P/E ratio is -3.31. In terms of profitability, UTMD's ROE is +0.10%, compared to NXGL's ROE of -0.55%. Regarding short-term risk, UTMD is less volatile compared to NXGL. This indicates potentially lower risk in terms of short-term price fluctuations for UTMD.Check NXGL's competition here
UTMD vs NXGLW Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, NXGLW has a market cap of 8.6M. Regarding current trading prices, UTMD is priced at $66.94, while NXGLW trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas NXGLW's P/E ratio is -0.08. In terms of profitability, UTMD's ROE is +0.10%, compared to NXGLW's ROE of -0.55%. Regarding short-term risk, UTMD is less volatile compared to NXGLW. This indicates potentially lower risk in terms of short-term price fluctuations for UTMD.Check NXGLW's competition here
UTMD vs NSTG Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, UTMD is priced at $66.94, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas NSTG's P/E ratio is -0.03. In terms of profitability, UTMD's ROE is +0.10%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, UTMD is less volatile compared to NSTG. This indicates potentially lower risk in terms of short-term price fluctuations for UTMD.Check NSTG's competition here
UTMD vs LUCY Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, LUCY has a market cap of 4.8M. Regarding current trading prices, UTMD is priced at $66.94, while LUCY trades at $1.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas LUCY's P/E ratio is -0.52. In terms of profitability, UTMD's ROE is +0.10%, compared to LUCY's ROE of -0.00%. Regarding short-term risk, UTMD is less volatile compared to LUCY. This indicates potentially lower risk in terms of short-term price fluctuations for UTMD.Check LUCY's competition here
UTMD vs MHUA Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, MHUA has a market cap of 3.2M. Regarding current trading prices, UTMD is priced at $66.94, while MHUA trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas MHUA's P/E ratio is 0.32. In terms of profitability, UTMD's ROE is +0.10%, compared to MHUA's ROE of +0.06%. Regarding short-term risk, UTMD is less volatile compared to MHUA. This indicates potentially lower risk in terms of short-term price fluctuations for UTMD.Check MHUA's competition here
UTMD vs GMVD Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, UTMD is priced at $66.94, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas GMVD's P/E ratio is -0.01. In terms of profitability, UTMD's ROE is +0.10%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, UTMD is less volatile compared to GMVD. This indicates potentially lower risk in terms of short-term price fluctuations for UTMD.Check GMVD's competition here
UTMD vs GMVDW Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, UTMD is priced at $66.94, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas GMVDW's P/E ratio is N/A. In terms of profitability, UTMD's ROE is +0.10%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, UTMD is less volatile compared to GMVDW. This indicates potentially lower risk in terms of short-term price fluctuations for UTMD.Check GMVDW's competition here
UTMD vs POAI Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, POAI has a market cap of 1.5M. Regarding current trading prices, UTMD is priced at $66.94, while POAI trades at $2.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas POAI's P/E ratio is -0.01. In terms of profitability, UTMD's ROE is +0.10%, compared to POAI's ROE of +4.25%. Regarding short-term risk, UTMD is less volatile compared to POAI. This indicates potentially lower risk in terms of short-term price fluctuations for UTMD.Check POAI's competition here
UTMD vs AVGR Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, UTMD is priced at $66.94, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas AVGR's P/E ratio is -0.05. In terms of profitability, UTMD's ROE is +0.10%, compared to AVGR's ROE of +17.82%. Regarding short-term risk, UTMD is less volatile compared to AVGR. This indicates potentially lower risk in terms of short-term price fluctuations for UTMD.Check AVGR's competition here
UTMD vs GCTK Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, GCTK has a market cap of 856.9K. Regarding current trading prices, UTMD is priced at $66.94, while GCTK trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas GCTK's P/E ratio is N/A. In terms of profitability, UTMD's ROE is +0.10%, compared to GCTK's ROE of -26.59%. Regarding short-term risk, UTMD is less volatile compared to GCTK. This indicates potentially lower risk in terms of short-term price fluctuations for UTMD.Check GCTK's competition here
UTMD vs LUCYW Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, LUCYW has a market cap of 320.5K. Regarding current trading prices, UTMD is priced at $66.94, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas LUCYW's P/E ratio is N/A. In terms of profitability, UTMD's ROE is +0.10%, compared to LUCYW's ROE of -0.00%. Regarding short-term risk, UTMD is less volatile compared to LUCYW. This indicates potentially lower risk in terms of short-term price fluctuations for UTMD.Check LUCYW's competition here
UTMD vs WOK Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, WOK has a market cap of 8K. Regarding current trading prices, UTMD is priced at $66.94, while WOK trades at $1.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas WOK's P/E ratio is N/A. In terms of profitability, UTMD's ROE is +0.10%, compared to WOK's ROE of -0.07%. Regarding short-term risk, UTMD is less volatile compared to WOK. This indicates potentially lower risk in terms of short-term price fluctuations for UTMD.Check WOK's competition here
UTMD vs IIN Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, IIN has a market cap of 0. Regarding current trading prices, UTMD is priced at $66.94, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas IIN's P/E ratio is 226.45. In terms of profitability, UTMD's ROE is +0.10%, compared to IIN's ROE of -0.00%. Regarding short-term risk, UTMD is more volatile compared to IIN. This indicates potentially higher risk in terms of short-term price fluctuations for UTMD.Check IIN's competition here
UTMD vs HRC Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, HRC has a market cap of 0. Regarding current trading prices, UTMD is priced at $66.94, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas HRC's P/E ratio is 41.92. In terms of profitability, UTMD's ROE is +0.10%, compared to HRC's ROE of +0.14%. Regarding short-term risk, UTMD is more volatile compared to HRC. This indicates potentially higher risk in terms of short-term price fluctuations for UTMD.Check HRC's competition here
UTMD vs ARTC Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, ARTC has a market cap of 0. Regarding current trading prices, UTMD is priced at $66.94, while ARTC trades at $0.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas ARTC's P/E ratio is N/A. In terms of profitability, UTMD's ROE is +0.10%, compared to ARTC's ROE of N/A. Regarding short-term risk, UTMD is more volatile compared to ARTC. This indicates potentially higher risk in terms of short-term price fluctuations for UTMD.Check ARTC's competition here
UTMD vs APR Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, APR has a market cap of 0. Regarding current trading prices, UTMD is priced at $66.94, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas APR's P/E ratio is 22.59. In terms of profitability, UTMD's ROE is +0.10%, compared to APR's ROE of +9.81%. Regarding short-term risk, UTMD is more volatile compared to APR. This indicates potentially higher risk in terms of short-term price fluctuations for UTMD.Check APR's competition here
UTMD vs ATRS Comparison February 2026
UTMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 214.5M. In comparison, ATRS has a market cap of 0. Regarding current trading prices, UTMD is priced at $66.94, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.24, whereas ATRS's P/E ratio is 14.95. In terms of profitability, UTMD's ROE is +0.10%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, UTMD is more volatile compared to ATRS. This indicates potentially higher risk in terms of short-term price fluctuations for UTMD.Check ATRS's competition here